Hummingbird Bioscience, a startup centered on creating new therapies for most cancers and different ailments, introduced as we speak it has added $6 million to its beforehand introduced Series B, bringing the spherical’s whole to $25 million.
The extension was led by SK Holdings, and included participation from returning traders together with Heritas Capital and SEEDS Capital, the funding arm of Enterprise Singapore, a authorities company that helps small- to medium-sized companies.
This brings Hummingbird Bioscience’s whole raised to date to $65 million. The firm says it prolonged its Series B as a result of the spherical was oversubscribed. The new funding will likely be used to take therapies Hummingbird Bioscience is creating to medical trials extra rapidly, and broaden analysis and improvement for its early stage pipeline.
Heritas Capital Management govt director and CEO Chik Wai Chiew mentioned in a press assertion that “Heritas Capital is happy to proceed our backing of the Hummingbird group since main its Series A prolonged spherical. Even because the COVID-19 pandemic has resulted in a slow-down in investing, we’re conscious that backing revolutionary biotech firms, particularly gamers resembling Hummingbird, to develop cures for addressing sufferers’ wants stays our precedence.”
The firm revealed information earlier this yr on two antibodies, each oncology therapies, and expects to make regulatory submissions to start out Phase 1 research within the second half of this yr.
Hummingbird Bioscience has places of work in Singapore, Houston and South San Francisco and strategic collaborations with Cancer Research United Kingdom and Amgen. It was beforehand awarded a product improvement grant from the Cancer Prevention and Research Institute of Texas.